Biopharmaceutical firm Juventas Cell Therapy has raked in over 400 million yuan ($62 million) in a Series C round. Juventas’s fresh funding was co-led by CICC Capital’s sub-fund and Oceanpine Capital.
Founded in June 2018, Juventas Cell Therapy Ltd. is a biomedical enterprise focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, which has in-depth cooperation with national first-class institutes and clinical research centers and is committed to building a leading platform for clinical transformation and commercialization of cell therapy, accelerating cell therapy innovation, clinical application and industrialization. Juventas creates safe, efficient and accessible immune cell therapy products for patients through strict product production and quality systems. CNCT19, the first product with Chinese independent intellectual property rights, has obtained two new drug clinical trial licenses from the National Medical Products Administration (NMPA), and is used to treat relapsed or refractory acute lymphoblastic leukemia and relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Recruitment of clinical trial subjects is currently underway to accelerate the listing process and benefit Chinese patients with hematological tumors. Meanwhile, the company continues to build highly scalable and competitive innovation pipelines, covering hematologic tumor pipelines, solid tumor pipelines and forward-looking general platform pipelines. In addition, the company has a world-class R&D platform, process development platform, quality control system and commercial production base. The company has a 2000 square metres R&D center in Beijing, and a nearly 10,000 square metres production base in Tianjin for R&D, transformation and commercialization of immune cell drugs that meets GMP standards.
Source: Oceanpine Capital
